← Feed

$GANX

3 theses
bullish 100%neutral 0%bearish 0%
Avg return (1d)
—
Win rate (1d)
— (0 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 15, 4:30 PM ET
$GANXr/pennystocksGeneral Discussionbullish
u/Keeg117 · 194d agono track record yet
“Disclosure: I am currently an investor in $GANX.”

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17.

Gain Therapeutics is developing the first drug to reverse Parkinson's disease, with recent human data showing 81% reduction in brain toxins and significant physical improvement in 90 days. A major biomarker data reveal on March 17–18 at the AD/PD Conference could validate disease modification and trigger a multi-billion-dollar buyout from Big Pharma.

At post $2.51Now $1.71-31.9% since postedas of Sep 15, 4:30 PM ET
original post →
$GANXr/pennystocksStock Infobullish
u/Correct_Proposal_409 · 271d ago1 prior · awaiting results

$GANX- CEO interview just came out-- dispels any misconceptions

CEO interview reveals strong biomarker data (GluSph) showing disease modification in Parkinson's treatment with multiple downstream improvements (mitochondrial dysfunction, lysosomal, A-syn aggregation). Author views yesterday's sell-off as an overreaction and believes this is a disease-modifying drug with potential to be the first of its kind, making it an attractive buy at current discount.

Now $1.71as of Sep 15, 4:30 PM ET
original post →
$GANXr/pennystocksGeneral Discussionbullish
u/Correct_Proposal_409 · 279d ago1 prior · awaiting results

$GANX — The Most Asymmetric Setup I’ve Ever Seen (And the Clock Is Ticking)

Gain Therapeutics' GT-02287 shows unprecedented potential as the first disease-modifying drug for Parkinson's, with consistent positive data at every stage (preclinical through phase 1b), no safety issues, and CEO confidence telegraphing imminent data readout within days. Even worst-case scenario (efficacy limited to GBA1 subgroup) de-risks the investment, with realistic 100%+ overnight upside on biomarker confirmation and multi-billion-dollar upside potential from a ~$250M market cap.

Now $1.71as of Sep 15, 4:30 PM ET
original post →

End of results.